I. Buck

发表

Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP.

G. Chessari, P. Williams, E. J. Lewis, 2015, Journal of medicinal chemistry.

Design, Synthesis, and Structure−Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists

N. Shankley, I. Buck, S. Kalindjian, 2000 .

Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP).

G. Chessari, P. Williams, E. Chiarparin, 2017, Journal of medicinal chemistry.

Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.

K. Kondo, A. Woolford, T. Heightman, 2022, ACS medicinal chemistry letters.

Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.

C. Low, C. Austin, I. Buck, 2006, Journal of medicinal chemistry.

Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.

J. Black, C. Low, N. Shankley, 2005, Journal of medicinal chemistry.

Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.

J. Black, C. Low, H. Broughton, 2000, Journal of medicinal chemistry.

Improving the Affinity and Selectivity of a Nonpeptide Series of Cholecystokinin‐B/Gastrin Receptor Antagonists Based on the Dibenzobicyclo(2.2.2)octane Skeleton.

C. Low, M. Hudson, M. Tozer, 1996 .

A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane.

M. Bodkin, C. Low, I. Buck, 1994, Journal of medicinal chemistry.

Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons.

J. G. Vinter, C. Low, M. Hudson, 1996, Journal of medicinal chemistry.

A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one

G. Chessari, P. Williams, G. Saxty, 2018, Journal of medicinal chemistry.

Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists.

J. G. Vinter, C. Low, N. Shankley, 2005, Journal of medicinal chemistry.

Conversion of guanosine into acyclovir and its 6-deoxy derivative

C. Reese, I. Buck, A. Eleuteri, 1994 .

Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists.

C. Low, C. Austin, D. Sykes, 2007, Journal of medicinal chemistry.

Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.

J. Black, D. Sykes, I. Buck, 2007, Journal of medicinal chemistry.

CCK(2) receptor antagonists containing the conformationally constrained phenylalanine derivatives, including the new amino acid Xic.

M. Tozer, I. Buck, S. Gibson, 2002, European journal of medicinal chemistry.

4-Chlorobenzyl sulfonamide and sulfamide derivatives of histamine homologues: the design of potent histamine H3 receptor antagonists.

M. Tozer, I. Buck, I. M. Mcdonald, 1999, Bioorganic & medicinal chemistry letters.

ω-(Imidazol-4-yl)alkane-1-sulfonamides: a new series of potent histamine H3 receptor antagonists

M. Tozer, I. Buck, S. Kalindjian, 2002 .

ω-(Imidazol-4-yl)alkane-1-sulfonamide: A New Series of Potent Histamine H3 Receptor Antagonists.

M. Tozer, I. Buck, S. Kalindjian, 2010 .

An unambiguous synthesis of adenylosuccinic acid and its constituent nucleoside

C. Reese, I. Buck, 1990 .

Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.

Christopher W Murray, Paul N. Mortenson, Valerio Berdini, 2015, ACS medicinal chemistry letters.

Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

C. Murray, V. Berdini, L. Fazal, 2021, Journal of medicinal chemistry.

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

C. Murray, V. Berdini, J. Castro, 2018, Journal of medicinal chemistry.

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.

M. Noble, J. Endicott, G. Chessari, 2021, Journal of medicinal chemistry.

Improving the affinity and selectivity of a nonpeptide series of cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane skeleton.

C. Low, M. Hudson, M. Tozer, 1995, Journal of medicinal chemistry.